WO1998043993A3 - Nucleic acid catalysts - Google Patents
Nucleic acid catalysts Download PDFInfo
- Publication number
- WO1998043993A3 WO1998043993A3 PCT/US1998/006231 US9806231W WO9843993A3 WO 1998043993 A3 WO1998043993 A3 WO 1998043993A3 US 9806231 W US9806231 W US 9806231W WO 9843993 A3 WO9843993 A3 WO 9843993A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- acid catalysts
- synthesis
- methods
- acid molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Catalysts (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU65917/98A AU6591798A (en) | 1997-03-31 | 1998-03-30 | Nucleic acid catalysts |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4290597P | 1997-03-31 | 1997-03-31 | |
US60/042,905 | 1997-03-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998043993A2 WO1998043993A2 (en) | 1998-10-08 |
WO1998043993A3 true WO1998043993A3 (en) | 1999-04-15 |
Family
ID=21924366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/006231 WO1998043993A2 (en) | 1997-03-31 | 1998-03-30 | Nucleic acid catalysts |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6591798A (en) |
WO (1) | WO1998043993A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9499818B2 (en) | 2007-10-26 | 2016-11-22 | BioMarin Technologies, B.V. | Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002514913A (en) * | 1996-12-19 | 2002-05-21 | エール ユニバーシティ | Bioreactive allosteric polynucleotide |
AU6522599A (en) * | 1998-10-23 | 2000-05-15 | Children's Medical Center Corporation | Use of a self-cleaving rna motif to modulate gene expression |
EP1092777A1 (en) * | 1999-10-15 | 2001-04-18 | Aventis Pharma S.A. | Self-cleaving RNA sequences and their use for the control of protein synthesis. |
US6831171B2 (en) | 2000-02-08 | 2004-12-14 | Yale University | Nucleic acid catalysts with endonuclease activity |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
WO2002081628A2 (en) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
AU2002316135B9 (en) | 2001-05-18 | 2009-05-28 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
CA2524255C (en) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
EP1622572B1 (en) | 2003-04-30 | 2017-12-20 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US20060200878A1 (en) | 2004-12-21 | 2006-09-07 | Linda Lutfiyya | Recombinant DNA constructs and methods for controlling gene expression |
EP3372676A1 (en) * | 2004-12-21 | 2018-09-12 | Monsanto Technology, LLC | Recombinant dna constructs and methods for controlling gene expression |
EP3199646A1 (en) | 2006-10-12 | 2017-08-02 | Monsanto Technology LLC | Plant micrornas and methods of use thereof |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
AU2010239779A1 (en) | 2009-04-24 | 2011-11-17 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating DMD |
DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
WO2013112053A1 (en) | 2012-01-27 | 2013-08-01 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019433A2 (en) * | 1994-01-12 | 1995-07-20 | Targetech, Inc. | Anti-hepatitis b poly- and oligonucleotides |
WO1996003152A1 (en) * | 1994-07-28 | 1996-02-08 | Georgetown University | Antisense oligonucleotides against hepatitis b viral replication |
WO1997010328A2 (en) * | 1995-07-13 | 1997-03-20 | Ribozyme Pharmaceuticals, Inc. | Compositions and method for modulation of gene expression in plants |
-
1998
- 1998-03-30 AU AU65917/98A patent/AU6591798A/en not_active Abandoned
- 1998-03-30 WO PCT/US1998/006231 patent/WO1998043993A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019433A2 (en) * | 1994-01-12 | 1995-07-20 | Targetech, Inc. | Anti-hepatitis b poly- and oligonucleotides |
WO1996003152A1 (en) * | 1994-07-28 | 1996-02-08 | Georgetown University | Antisense oligonucleotides against hepatitis b viral replication |
WO1997010328A2 (en) * | 1995-07-13 | 1997-03-20 | Ribozyme Pharmaceuticals, Inc. | Compositions and method for modulation of gene expression in plants |
Non-Patent Citations (4)
Title |
---|
BREAKER, R.R. & JOYCE, G.F.: "Inventing and improving ribozyme function: ...", TIBTECH, vol. 12, 1994, pages 268 - 275, XP002084353 * |
NISHIKAWA, F. ET AL.: "Selection in vitro of trans-acting genomic hepatitis delta virus (HDV) ribozymes", EUR. J. BIOCHEM., vol. 237, 1996, pages 712 - 718, XP002084352 * |
PERROTTA, A.T. & BEEN, M.D.: "Core sequences and a cleavage site wobble pair required for HDV antigenomic ribozyme self-cleavage", NUCLEIC ACIDS RESEARCH, vol. 24, no. 7, 1996, pages 1314 - 1321, XP000582452 * |
TANG, J. & BREAKER, R.R.: "Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection", RNA, vol. 3, 1997, pages 914 - 925, XP002084354 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9499818B2 (en) | 2007-10-26 | 2016-11-22 | BioMarin Technologies, B.V. | Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene |
US9528109B2 (en) | 2007-10-26 | 2016-12-27 | Biomarin Technologies B.V. | Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA |
Also Published As
Publication number | Publication date |
---|---|
WO1998043993A2 (en) | 1998-10-08 |
AU6591798A (en) | 1998-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998043993A3 (en) | Nucleic acid catalysts | |
WO1999016871A3 (en) | Nucleic acid catalysts with endonuclease activity | |
ID17927A (en) | CATALYST CATALYST OF DOUBLE METALS, HIGH ACTIVITY | |
AU3666097A (en) | Novel catalytic rna molecules | |
WO1998008974A3 (en) | Catalytic nucleic acid and its medical use | |
WO1997026270A3 (en) | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | |
ZA991496B (en) | Deeply reduced oxidation catalyst and its use for catalyzing liquid phase oxidation reactions. | |
DE69812901D1 (en) | CATALYTIC PRODUCTION OF PENTAFLUORPROPEN | |
ZA981883B (en) | Catalysts and methods for catalytic oxidation | |
BR9804251B1 (en) | process for catalytic nitrile hydrogenation, and spongy cobalt catalyst. | |
WO1996021730A3 (en) | Ribozymes with rna protein binding site | |
AU5445598A (en) | Selective catalytic no reduction utilizing urea without catalyst fouling | |
ZA946133B (en) | Method of improving catalyst activity, improved catalysts and their use. | |
HUP9601699A3 (en) | Bisphosphins, metalcomplexes, preparation and use thereof as catalysts for asymmetrical reactions | |
ZA983217B (en) | Process for the preparation of high activity hydrocarbon synthesis catalysts and catalyst composition | |
WO1998050530A3 (en) | Enzymatic nucleic acids: synthesis, selection and use | |
AU3354499A (en) | Human mekk proteins, corresponding nucleic acid molecules, and uses therefor | |
ZA9710163B (en) | Novel carboxylesterase nucleic acid molecules, proteins and uses thereof. | |
AU7925498A (en) | Alumina extrudates, methods for preparing and use as catalysts or cataly st supports | |
WO2001052985A3 (en) | Gel catalysts and methods for their use in catalytic dehydrogenation processes | |
HUP9601489A2 (en) | High activity catalytic system for the synthesis of poly (ethyleneterephthalate), polyethyleneterephthalate produced thereby and the use thereof | |
WO2001059102A3 (en) | Nucleozymes with endonuclease activity | |
ZA200101737B (en) | Nucleic acid molecules which code for enzymes with fructosyltransferase activity and use thereof. | |
AUPP810399A0 (en) | Catalytic molecules | |
WO1999011799A3 (en) | Human aminopeptidase p gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998541899 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |